INmune Bio Inc. (INMB)
| Market Cap | 38.02M -79.4% |
| Revenue (ttm) | n/a +257.1% |
| Net Income | -41.60M |
| EPS | -1.61 |
| Shares Out | 26.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 240,374 |
| Open | 1.410 |
| Previous Close | 1.430 |
| Day's Range | 1.410 - 1.505 |
| 52-Week Range | 1.090 - 11.640 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 5.40 (+277.62%) |
| Earnings Date | May 7, 2026 |
About INMB
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatmen... [Read more]
Financial Performance
In 2025, INmune Bio's revenue was $50,000, an increase of 257.14% compared to the previous year's $14,000. Losses were -$45.93 million, 9.15% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for INMB stock is "Buy." The 12-month stock price target is $5.4, which is an increase of 277.62% from the latest price.
News
INmune Bio Earnings Call Transcript: Q1 2026
Q1 2026 saw reduced net loss and R&D expenses, with $21.4M in cash supporting operations into 2027. Regulatory and manufacturing milestones for CORDStrom are progressing, while XPro advances with new imaging data and partnership exploration.
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update
BOCA RATON, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's inna...
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases
LONDON, UK and BOCA RATON, FL, May 05, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune Bio”), a clinical-stage biotechnology company, and Anthony Nolan, a pioneering UK-based charity ...
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage infla...
INmune Bio announces new preclinical data for INB03
INmune Bio (INMB) announces new preclinical data for INB03. The data will be presented at the American Association for Cancer Research, AACR, Annual Meeting 2026 in San Diego on April
INmune Bio Earnings Call Transcript: Q4 2025
Advanced CORDStrom for RDEB towards regulatory filings, completed phase II trials for XPro in Alzheimer's and INKmune in prostate cancer, and raised $27.5M in equity. Cash runway extends through Q1 2027, with key regulatory milestones expected in 2026–2027.
INmune Bio Inc. Announces 2025 Results and Provides Business Update
BOCA RATON, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announces its fina...
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
Boca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it will host a confer...
INmune Bio’s MINDFuL trial presented as succesful example in Alzheimer’s
INmune Bio (INMB) announced that Malu Gamez Tansey, Professor of Neurology at Indiana University School of Medicine, will feature the company’s Phase 2 MINDFuL trial of XPro – pegipanermin –
INmune Bio upgraded to Buy from Neutral at Lucid Capital
Lucid Capital upgraded INmune Bio (INMB) to Buy from Neutral with a price target of $9, up from $2. The firm is now factoring into the model the company’s CORDStrom
INmune Bio Transcript: Study update
Mission EB phase III trial showed CORDStrom, a pooled umbilical cord-derived cell therapy, significantly reduced itch and pain, improved wound healing, and was safe in children with RDEB. Sustained benefits were observed at six months, with the greatest impact in severe cases. Regulatory submissions are planned for 2024.
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar
Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595 Webinar on February 27 at 9:30 AM ET will have key opinion leaders discu...
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
Clinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study
INmune Bio announces FDA alignment on phase 2b/3 registration pathway
INmune Bio (INMB) announced that it received the official minutes from its End-of-Phase 2 meeting with the U.S. Food and Drug Administration, FDA. The minutes confirm regulatory alignment on the
INmune Bio submits pre-submission package for CORDStrom with MHRA
INmune Bio (INMB) has formally submitted its pre-submission package for CORDStrom with the United Kingdom’s Medicines and Healthcare Products Regulatory Agency. This early engagement step is designed ...
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
Pre-submission package is a process that facilitates early feedback from the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA), designed to streamline the final approval p...
INmune Bio CEO says ‘well positioned for continued execution’
INmune Bio (INMB) presented a letter to investors from David Moss, CEO, which read in part, “As we reflect on 2025, I want to thank you for your continued support
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
Boca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO...
INmune Bio publishes study on INmune’s CORDStrom platform
INmune Bio (INMB) announces a recently published overview of future applications and research areas for mesenchymal stromal cell therapies, such as INmune’s CORDStrom platform. The article, titled, “F...
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom™ Platform
Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage inflammation and immunology company, announces a recently published over...
INmune Bio announces neuroimaging data from Phase 2 MINDFuL trial
INmune Bio (INMB) announces new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer’s disease and elevated neuroinflammation. The results will be presented at
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients
Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfu...
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical...
INmune Bio reports Q3 EPS (24c), consensus (32c)
As of September 30, the company had cash and cash equivalents of approximately $27.7M.
INmune Bio Earnings Call Transcript: Q3 2025
Q3 2025 saw reduced net loss and R&D spend, with CORDStrom advancing toward UK and US filings for RDEB, XPro showing promise in Alzheimer's, and INKmune meeting key endpoints in prostate cancer. Cash runway extends into Q4 2026.